Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Agnico Eagle Mines Ltd (AEM) Price & Performance

Adaptive Biotechnologies CorpTrade
Agnico Eagle Mines LtdTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Agnico Eagle Mines Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Agnico Eagle Mines Ltd trades at $182.91 (market cap $91.28B). The key difference: Agnico Eagle Mines Ltd is far larger — about 22.5× Adaptive Biotechnologies Corp's market cap, and Agnico Eagle Mines Ltd pays a 1% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTAEM
Market Cap
$4.05B$91.28B
Sector
HealthBasic Materials
52-Week High
$25.45$252.19
52-Week Low
$12.30$130.23
Enterprise Value
$4.12B$88.12B
Dividend Yield
1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

Agnico Eagle Mines Ltd

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Agnico Eagle Mines Ltd

Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.

Read more on AEM